- Home
- NL vs CLLS Comparison
NL vs CLLS Comparison
Compare NL & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NL | CLLS |
|---|---|---|
| Founded | 1891 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.9M | 299.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NL | CLLS |
|---|---|---|
| Price | $5.50 | $4.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 26.0K | ★ 130.5K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | ★ 10.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $159,004,000.00 | $82,551,000.00 |
| Revenue This Year | $15.75 | N/A |
| Revenue Next Year | $2.44 | $58.00 |
| P/E Ratio | $28.47 | ★ N/A |
| Revenue Growth | 5.52 | ★ 129.04 |
| 52 Week Low | $5.04 | $1.10 |
| 52 Week High | $9.42 | $5.48 |
Technical Indicators
Market Signals| Indicator | NL | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 59.17 |
| Support Level | $5.04 | $4.52 |
| Resistance Level | $5.75 | $5.35 |
| Average True Range (ATR) | 0.26 | 0.29 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 76.31 | 64.28 |
Price Performance
Historical ComparisonAbout NL NL Industries Inc.
NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.